CN1323348A - 猪促生长素传递系统 - Google Patents
猪促生长素传递系统 Download PDFInfo
- Publication number
- CN1323348A CN1323348A CN99812256A CN99812256A CN1323348A CN 1323348 A CN1323348 A CN 1323348A CN 99812256 A CN99812256 A CN 99812256A CN 99812256 A CN99812256 A CN 99812256A CN 1323348 A CN1323348 A CN 1323348A
- Authority
- CN
- China
- Prior art keywords
- cell
- pst
- expression cassette
- secretion signal
- host
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 13
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 13
- 230000014509 gene expression Effects 0.000 claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
- 229920001184 polypeptide Polymers 0.000 claims abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 20
- 239000002775 capsule Substances 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 44
- 241001465754 Metazoa Species 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 230000003914 insulin secretion Effects 0.000 claims description 20
- 239000007943 implant Substances 0.000 claims description 12
- 238000005192 partition Methods 0.000 claims description 11
- 229940072056 alginate Drugs 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 claims description 7
- 150000001413 amino acids Chemical group 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 210000003098 myoblast Anatomy 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 239000003016 pheromone Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 1
- 230000037451 immune surveillance Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 description 18
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 235000019786 weight gain Nutrition 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 208000037816 tissue injury Diseases 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- 229940038773 trisodium citrate Drugs 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 210000002955 secretory cell Anatomy 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SCPRYBYMKVYVND-UHFFFAOYSA-N 2-[[2-[[1-(2-amino-4-methylpentanoyl)pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)CC(N)C(=O)N1CCCC1C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(O)=O SCPRYBYMKVYVND-UHFFFAOYSA-N 0.000 description 1
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 1
- UWIQWPWWZUHBAO-ZLIFDBKOSA-N Ala-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)CC(C)C)C(O)=O)=CNC2=C1 UWIQWPWWZUHBAO-ZLIFDBKOSA-N 0.000 description 1
- DEWWPUNXRNGMQN-LPEHRKFASA-N Ala-Met-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N DEWWPUNXRNGMQN-LPEHRKFASA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WDXLKVQATNEAJQ-BQBZGAKWSA-N Gly-Pro-Asp Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WDXLKVQATNEAJQ-BQBZGAKWSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- WDTLNWHPIPCMMP-AVGNSLFASA-N Met-Arg-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O WDTLNWHPIPCMMP-AVGNSLFASA-N 0.000 description 1
- NTYQUVLERIHPMU-HRCADAONSA-N Met-Phe-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N NTYQUVLERIHPMU-HRCADAONSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091008747 NR2F3 Proteins 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000584803 Xanthosia rotundifolia Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 101150108487 pst2 gene Proteins 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 102220023257 rs387907546 Human genes 0.000 description 1
- 102220023258 rs387907548 Human genes 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
本发明公开了用于传递外源多肽(如促生长素等生长激素)至宿主中的表达构建体。在本发明一个应用中,将表达构建体导入非宿主重组细胞,该细胞包封于半渗透膜中,用于植入宿主。半渗透膜抑制免疫监视和细胞排斥事件,从而可以使用非宿主的高表达重组细胞。
Description
发明领域
本发明涉及传递外源多肽至宿主中的表达构建体。本发明还涉及包括该表达构建体的重组细胞和包括该重组细胞的半渗透胶囊。
发明背景
在哺乳动物中,促生长素(生长激素)通常由脑垂体分泌。但是,已经证实向猪给予外源促生长素会提高摄食效率15-20%,增加日增重10-15%,降低身体脂肪10-20%,增加瘦肉含量5-10%,降低摄食量。令人遗憾的是,促生长素(它是190个氨基酸的小蛋白质)对胃酸和蛋白降解敏感,因此需要每日注射才会有效果。当前,福利和道德的考虑使得使用气动pST注射枪不受欢迎,每日用药的费用也限制了其大规模的使用。
基因治疗的最新进展已经发展出了新的策略,无需依赖自体靶细胞和免疫抑制治疗,而使用包封在半渗透藻酸盐-聚-L-赖氨酸-藻酸盐(APA)膜中的转染细胞。APA胶囊环境允许细胞存活和生长,因此转染细胞保持存活并在较长时间内分泌生长因子。APA对小蛋白是可通透的,因此基因表达可以通过外源机制控制。APA屏障抑制免疫监视和细胞排斥事件,从而可以在胶囊中使用非宿主、高表达细胞。APA屏障也可能阻止宿主受体中转染细胞不受控制的增殖。APA胶囊可以取出,可能还可以再次使用,从而打消对于食用转基因材料的担忧。而且,如果胶囊被严重的组织创伤损害,正常的宿主-移植物排斥就会摧毁植入的细胞。
发明概述
发明人现已发现,在基因序列导入宿主细胞中之前,胰岛素分泌信号与异源基因序列的连接导致外源基因产物分泌水平出乎意料的增长。这一发现已经导致开发出了改进的基因传递系统,包括包封重组细胞植入宿主中。
因而,第一方面,本发明提供了一种表达盒,包括编码胰岛素分泌信号的序列,其与编码一种多肽的异源序列有效连接。
“异源序列”是指不是编码胰岛素的序列的序列。
“有效连接”是指胰岛素分泌信号序列与异源编码序列邻接并位于同一阅读框。
优选的胰岛素分泌信号是具有SEQ ID NO:1所示氨基酸序列的胰岛素分泌信号。但是,本领域技术人员会认识到,可以对分泌信号进行多种修饰而不会对信号的生物活性有不利影响。例如,这可以通过在肽序列中进行各种改变或通过保守或非保守的氨基酸插入、缺失和取代(如D-氨基酸,脱氨基酸)实现,所述改变如硫酸化、磷酸化、硝化和卤化,只要这些改变不会对分泌信号的总体生物活性有不利影响。因此,在表达盒中包括已经以上述一种或多种方式修饰的胰岛素分泌信号被认为包括在本发明之中。
异源序列可以编码除胰岛素以外的目标多肽。例如,异源序列可以编码激素、细胞因子、受体激动剂或拮抗剂、信息素或酶。在优选实施方案中,异源序列编码生长激素。优选,生长激素是促生长素。
本发明第二方面提供了包括第一方面的表达盒的载体。该载体可以是将表达盒导入细胞的任何合适的载体。合适载体包括病毒载体和细菌质粒。
本发明第一方面的表达盒或第二方面的载体还可以包括一个或多个调控基因表达的元件。合适调控元件的实例包括褪黑素应答元件(MRE)(见Schrader et al.,1996,此处全文引入作为参考),和/或雷帕霉素介导转录因子(见Magari et al.,1997,此处全文引入作为参考)。在优选实施方案中,调控元件可以实现目标多肽的脉动表达。
本发明第三方面提供了一种重组细胞,它包括本发明第一方面的表达盒。
重组细胞可以是细菌、真菌、昆虫或哺乳动物细胞。在优选实施方案中,重组细胞是哺乳动物细胞。在进一步优选的实施方案中,细胞是大鼠成肌细胞(L6)。
本发明第四方面提供生产多肽的方法,包括在可以表达和分泌所述多肽的条件下培养第三方面的重组细胞,可选地包括分离该多肽。
本发明的重组细胞可以包封在半渗透基质中以传递或植入人体。
因此,本发明第五方面提供植入宿主的胶囊,该胶囊包括包封本发明第三方面的一种或多种重组细胞的半渗透膜。
在优选实施方案中,半渗透膜是藻酸盐-聚-L-赖氨酸-藻酸盐(APA)膜。APA半渗透膜的制备见Basic et al.,1996,该文献全文引入作为参考。
本发明第六方面提供向宿主给予多肽的方法,包括向宿主给予本发明第一方面的表达盒。
本发明第七方面提供向宿主给予多肽的方法,包括在宿主中植入本发明第五方面的胶囊。
宿主可以是任何动物或人。在优选实施方案中,宿主是家畜。在进一步优选的实施方案中,宿主选自放牧牛、圈养牛、奶牛、猪和家禽。
本领域技术人员会认识到,本发明提供了传递遗传物质到宿主中的改进系统。胰岛素分泌信号与生物活性多肽的连接导致从重组细胞分泌的多肽增加。分泌后,分泌信号可以切除,留下生物活性多肽。重组细胞包封在半渗透膜中时,可以分泌相当数量的生物活性多肽,借助半渗透膜可以通过外来方式控制基因表达。植入包封的重组细胞的优势在于植入需要的手术最轻。此外,半渗透膜减少了免疫监视和细胞排斥,这意味着非宿主细胞可以用在胶囊中。
在优选实施方案中,半渗透膜是持久耐用的,从而具有限制细胞生长并阻止在宿主受体中的不受控制增殖的优势。胶囊的另一个优势在于它们可以被取出并再次使用。
为了更清楚地理解本发明的特点,以下参照非限定性实施例和附图叙述本发明的优选方式。
附图简述:
图1:胰岛素分泌信号-pST基因构建体。
图2:胰岛素分泌信号-pST肽序列。
图3:对照和pST-L6IXS处理猪的增重率(从0天起)。
图4:对照和pST-L6IXS处理猪的增重百分比。
图5:对照和pST-L6IXS处理动物的血浆pST水平。
图6:Plate 1-pST-L6IXS胶囊给药部位评估。
Plate 2-pST-L6IXS胶囊置于培养基中进行来自体内的评估。
图7:从宿主动物取出后24小时从胶囊分泌pST的来自体内的评估。
图8:在给予pST胶囊之前(白柱体)和一周后(黑柱体)平均血浆pST(3小时@30分钟间隔)(*显著性)
图9:分别植入分泌25ng/ml和500ng/ml的胶囊的两只猪206和228的每日血浆pST浓度。
图10:实施例4中的猪的增重率(ROG,公斤/日,黑方块)和P2背脂肪测定。
图11:植入pST分泌或对照免疫中性基因治疗(IGT)胶囊后公猪增重率(ROG)(±SEM)。
图12:植入pST分泌或对照免疫中性基因治疗(IGT)胶囊后公猪背脂肪(P2)(+SEM)。
图13:植入pST分泌或对照免疫中性基因治疗(IGT)胶囊后公猪腰(眼)肌肉面积(+SEM)。
发明详述
实施例1:ISS-pST构建体的克隆
pST基因获自Southern Cross Biotechnology Pty Ltd的大肠杆菌。含有pST基因的质粒pMG939使用标准质粒制备技术从细菌中分离。设计用来扩增pST基因的PCR引物,在5’末端加入XhoⅠ位点,3’末端加入XbaⅠ位点,以进行连接。
修饰pST基因序列然后连接至来自前原胰岛素cDNA的分泌信号序列(ISS)。NheⅠ(GCTAGC)和XbaⅠ(TCTAGA)限制位点分别构建在ISS起始密码子之前pST 3’末端密码子之后,以便整合进pCI-neo质粒(Promega)。然后分离pST融合构建体并测序,以验证编码区(图1)。
大鼠成肌细胞(L6)用胰蛋白酶处理后2小时,用LipoTAXI(Stratagene)进行转染(pST基因整合细胞)。PST转染L6细胞克隆在培养物中维持,用G418选择,直至产生>107细胞。培养物上清的等分试样(2ml)在-20℃保存,直至用悉尼大学(Camden)的Dr P.Wynn首创的pST放射免疫试验(RIA)测定pST浓度。RIA敏感性被认为大于0.4ng/ml,CV为12.4%。多克隆抗血清用pST肽抗原在豚鼠中产生。RIA结果(表1)表明pST基因构建体产生一种蛋白(图2),它被由猪脑垂体纯化的天然形式pST产生的多克隆抗血清识别。L6克隆pCI/pst-1.5如下所述由修饰转染技术产生。
修饰转染法
一般说来,L6细胞粘附在培养板上,需要用胰蛋白酶解吸附才能传代;转染一般在24小时后进行。该方法产生分泌6-18ng/ml pST的L6细胞克隆(n=10)。胰蛋白酶处理2小时后,加入LipoTAXI(Promega)和ISS/pST质粒至L6细胞增加pST分泌速率10到20倍(>180ng/ml,n=5克隆)。该较高的pST分泌速率降低了促进生长所需的细胞数(胶囊数)。
表1:用ISS-pST转染的各克隆的浓度(ng/ml)
L6克隆 | pST(ng/ml) |
pCI/pst-1* | 182 |
pCI/pst-2* | 188 |
pCI/pst-3* | 188 |
pCI/pst-4* | 140 |
pCI/psr-5* | 200 |
pCI/pst-6 | 17 |
pCI/pst-7 | 12 |
pCI/pst-8 | 8 |
pCI/pst-9 | 9 |
pCI/pst-10 | 7 |
pCI/pst-11 | 7 |
pCI/pst-12 | 10 |
pCI/pst-13 | 8 |
pCI/pst-14 | 6 |
pCI/pst-15 | 18 |
实施例2:猪促生长素-大鼠成肌细胞(L6)免疫中性表达系统(pST-L6IXS)的制备
按照Basic et al,1996所述进行包封步骤,包括如下改进。
在室温下包封细胞,利用氯化钙(或乳酸钙)(100mM)使藻酸盐(1.5%w/v)液滴形成凝胶,然后立即用盐水(0.9%NaCl)洗涤,再重悬于聚-L-赖氨酸(0.05%)中5分钟。37℃氯化钙交联10分钟产生与细胞活力更相容的藻酸盐基质。
聚-L-赖氨酸包被和盐水洗涤之后,加入另一层藻酸盐。柠檬酸钠(55mM)室温处理4分钟软化胶囊至一定坚度,增加进一步操作的难度。柠檬酸钠处理4分钟显著降低细胞活力至<35%。柠檬酸钠处理之前将胶囊置于细胞滤过器使得37℃下处理1分钟提高细胞活力达>98%。
对包封方法的步骤和设备改进提高了包封的效率(时间和资源),细胞活力一般增加64%。
实施例3:pST-L6IXS植入猪的初步试验(1)
将pST-L6IXS给予生长中的小鼠获得的初步结果表明了较好的生长特性。在用公猪进行的初步试验(n=9,平均活体重61公斤)中,在不同部位给予不等量的pST-L6IXS(0天,每只动物:颈部肌肉,3个胶囊,i.m.;颈部,3个胶囊,s.c.;耳根部,10个胶囊,s.c.;颈部,20个胶囊,i.m.;颈部,29个胶囊,i.m.)。颈静脉穿刺采集血样(10ml),给药后-14、0、7、14、21、28和36天记录P2超声(us)测定结果。试验中全程监测pST-L6IXS给药部位的组织反应事件。36天将动物无痛处死,对躯体各部分进行分析(背部脂肪厚度,BF(mm);眼肌面积,EMA(cm);前臂骨长,BONE(cm);心脏重量,HEART(gm);脾脏重量,SPLEEN(gm);肝脏重量,LIVER(gm))并记录(见表2),回收pST-L6IXS。图3代表对照(con,平均值±SE,n=4)和各只pST-L6IXS处理猪的增重率(从0天起)。对照(con)(平均值±SE)和各只pST-L6IXS处理动物相对于pST-L6IXS处理的增重百分比在图4中示出。对照(平均值±SE)(con)和各只pST-L6IXS处理动物的血浆pST(ng/ml)通过放射免疫试验(RIA)确定并在图5中示出。处死时评价pST-L6IXS给药部位(图6,Plate 1,箭头),然后取出并置于培养基中进行来自体内的24小时pST分泌评估(图6,Plate 2)(图6)。在36天i.m.或s.c.给药均未观察到明显的组织损害或免疫反应。但是,置于耳部(s.c.)的胶囊似乎高度血管化,而且100%可回收。置于颈部的胶囊可回收的小于10%。
pST-L6IXS在体内36日仍有效,并且似乎在胶囊中增殖(Plate2),胶囊可以取出,从而打消对食用转基因材料的担忧。而且,如果胶囊受损(即由于严重的组织创伤),正常的宿主-移植物排斥会摧毁L6细胞,防止转染材料的增殖。小鼠和猪中进行的试验已经证实pST-L6IXS可有效改变血清pST,提高生长特性,还可能提高动物的免疫能力。
表2:pST-L6IXS初步试验:
公猪由Westmill piggery(Young,NSW)
在EMAI的高度安全猪舍进行试验
实施例4:pST-L6IXS植入猪的初步试验(2)
为了优化通过胶囊的pST-L6IXS传递,从而获得类似于每日注射pST的能量再分配的生长应答,进行了第二次初步试验。
如实施例1所述,制备了多种分泌速率(6-200ng/ml)的pST分泌细胞。对pST分泌细胞外加胁迫(即细菌污染)后,2-25ng/ml的pST分泌速率似乎是最稳定的(数据未示出)。因此,选择分泌约5ng/ml(克隆pCI/pst-14)和约10ng/ml(pCI/pst-12)的克隆进行该初步试验。在公猪(n=10,平均活体重78.1kg)耳根部以s.c.途径给予不同数量的胶囊(按照实施例2所述步骤制备)(表3)。
猪 | 胶囊数量 | 克隆 |
204 | 1 | a |
216 | 1 | b |
230 | 3 | a |
202 | 3 | b |
226 | 5 | a |
206 | 5 | b |
208 | 10 | a |
224 | 10 | b |
222 | 100 | a |
228 | 100 | b |
a=克隆pCI/pst-14(5ng/ml)
b=克隆pCI/pst-12(10ng/ml)
试验开始和结束时记录体重。动物分别圈养于围栏(2m2),并在控制的环境条件下(22℃)稳定一周。动物自由饮水,定量给予标准颗粒状食料(3kg/日@0:900hrs),记录每日残留。插管置于耳静脉(evc),24小时后开始取样。对照猪(即不给予pST胶囊)血浆(10毫升)每30分钟收集一次,共3小时。系列取样后,耳后部给予pST胶囊。通过evc收集血样(10毫升)(每日@11:00hrs),插管仍留置。处理(给予pST胶囊后7日)血浆(10ml)每30分钟收集一次,共3小时。处死和躯体分析在21日后活体重为约100kg时进行。然后由耳部回收pST胶囊,置于体外培养(进行pST分析)。评估胶囊植入部位的免疫应答(如淋巴细胞浸润)。
接受pST胶囊(分泌5到1000ng/ml)之前和之后7天,猪平均(3小时、30分钟间隔)血浆pST浓度测定结果示于图8。由图8可见,免疫中性pST(5-100ng/ml)分泌胶囊处理后1周,猪血浆pST明显减少。
个体间和个体中血浆pST浓度的变化在对照系列取样期间似乎更明显。这种现象反映在平均测定浓度的标准误中。此外,稳定基线和pST脉冲间隔(一般3-4小时)不能被设计来鉴别激素脉冲的计算机程序识别。但是,稳定基线和明显的pST脉冲在pST胶囊给药后一周的动物中可以观察到(图9)。
动物的增重率(ROG)似乎以剂量依赖方式对pST胶囊分泌有反应(图10)。30ng/ml的分泌率(即3个胶囊各分泌10ng/ml)似乎是观察到生长速率增加所需的最小剂量。大多数evc在21天保持有效,此时动物用巴比妥盐无痛处死以进行躯体分析。躯体背部脂肪分析(不计皮肤的P2)测定值进一步表明30ng/ml是pST胶囊给药21天内观察到能量再分配所需的最小剂量(图10)。
包括接受100个胶囊的动物在内,所有动物在试验过程中未观察到副反应,即增重下降或不利免疫应答。
实施例5:pST-L6IXS植入猪的初步试验(3)
实施例4后,进行试验以评估在处死前不同时间(即处死前2、4和6周)向猪给予最佳pST分泌速率/胶囊数对背部脂肪的影响。每个处理使用8只动物,8只动物用作对照(即无pST胶囊)。
增重率测定结果在图11中给出。
在全躯体冷冻(24小时@4℃)后进行背部脂肪测定(图12)。对距脊柱中心65毫米的第12肋骨记录P2测定值。观察到给予分泌pST的胶囊2、4和6周的猪背部脂肪较少约46%。给予pST IGT胶囊4周的动物背部脂肪反应差异更大,这可能与从多只这样的动物中不能回收胶囊有关。
分泌胶囊处理的猪腰部肌肉面积只有在pST IGT胶囊处理6周后才显著增加(22%)(图13)。
本领域技术人员会认识到,对本发明的具体技术方案可以进行多种改进和/或修饰,而不会偏离本发明的精神和范围。因此,本文所述的各种实施方案仅是示例性的而非限制性的。
参考文献
Basic et al.,遗传工程细胞的微包封和植入:体细胞基因治疗的新途径。Art.Cells,Blood subs and Immob.Biotech24(3):219-255。
Magari et al.,(1997)植入裸鼠的人源化基因治疗系统的药物动力学控制。J.Clin.Invest.100:2865-2872。
Schrader et al.,(1996)核受体R2R/ROR的天然单体应答元件的鉴定。它们也结合COUP-TF同型二聚体。J.Biol.Chem.271:19732-19736。序列表申请人:Commonwealth Scientific and Industrial ResearchOrganisation
Univetsity of Western Sydney(Nepean)
Pig Research and Development Corporation发明名称:猪促生长素传递系统在先申请号:PP6556在先申请日:1998-10-16序列数:3软件:PatentIn Ver.2.1SEQ ID NO:1长度:72类型:DNA有机体:人序列:1atggccctgt ggatgcgcct cctgcccctg ctggcgctgc tggccctctg gggacctgac 60ccagccgcag ccSEQ ID NO:2长度:666类型:DNA有机体:人工序列特征:其它信息:人工序列描述ISS-pST基因构建体序列:2gctagcatgg ccctgtggat gcgcctcctg cccctgctgg cgctgctggc cctctgggga 60cctgacccag ccgcagccct cgagatgttt ccagctatgc cactttcttc tctgttcgct 120aacgctgttc ttcgggccca gcacctgcac caactggctg ccgacaccta caaggagttt 180gagcgcgcct acatcccgga gggacagagg tactccatcc agaacgccca ggctgccttc 240tgcttctcgg agaccatccc ggcccccacg ggcaaggacg aggcccagca gagatcggac 300gtggagctgc tgcgcttctc gctgctgctc atccagtcgt ggctcgggcc cgtgcagttc 360ctcagcaggg tcttcaccaa cagcccggtg tttggcacct cagaccgcgt ctacgagaag 420ctgaaggacc tggaggaggg catccaggcc ctgatgcggg agctggagga tggcagcccc 480cgggcaggac agatcctcaa gcaaacctac gacaaatttg acacaaactt gcgcagtgat 540gacgcgctgc ttaagaacta cgggctgctc tcctgcttca agaaggacct gcacaaggct 600gagacatacc tgcgggtcat gaagtgtcgc cgcttcgtgg agagcagctg tgccttctag 660tctaga 666SEQ ID NO:3长度:217类型:PRT有机体:人工序列特征:其它信息:人工序列描述:ISS-pST肽序列序列:3Met Ala Leu Trp Met Arg Leu Leu Pro Leu Leu Ala Leu Leu Ala Leu1 5 10 15Trp Gly Pro Asp Pro Ala Ala Ala Leu Glu Met Phe Pro Ala Met Pro
20 25 30Leu Ser Ser Leu Phe Ala Asn Ala Val Leu Arg Ala Gln His Leu His
35 40 45Gln Leu Ala Ala Asp Thr Tyr Lys Glu Phe Glu Arg Ala Tyr Ile Pro
50 55 60Glu Gly Gln Arg Tyr Ser Ile Gln Asn Ala Gln Ala Ala Phe Cys Phe65 70 75 80Ser Glu Thr Ile Pro Ala Pro Thr Gly Lys Asp Glu Ala Gln Gln Arg
85 90 95Ser Asp Val Glu Leu Leu Arg Phe Ser Leu Leu Leu Ile Gln Ser Trp
100 105 110Leu Gly Pro Val Gln Phe Leu Ser Arg Val Phe Thr Asn Ser Leu Val
115 120 125Phe Gly Thr Ser Asp Arg Val Tyr Glu Lys Leu Lys Asp Leu Glu Glu
130 135 140Gly Ile Gln Ala Leu Met Arg Glu Leu Glu Asp Gly Ser Pro Arg Ala145 150 155 160Gly Gln Ile Leu Lys Gln Thr Tyr Asp Lys Phe Asp Thr Asn Leu Arg
165 170 175Ser Asp Asp Ala Leu Leu Lys Asn Tyr Gly Leu Leu Ser Cys Phe Lys
180 185 190Lys Asp Leu His Lys Ala Glu Thr Tyr Leu Arg Val Met Lys Cys Arg
195 200 205Arg Phe Val Glu Ser Ser Cys Ala Phe
210 215
Claims (27)
1.一种表达盒,包括编码胰岛素分泌信号的序列,该序列与编码一种多肽的异源序列有效连接。
2.权利要求1的表达盒,其中胰岛素分泌信号具有SEQ ID NO:1所示氨基酸序列。
3.权利要求1的表达盒,其中胰岛素分泌信号是修饰的胰岛素分泌信号,具有与氨基酸序列为SEQ ID N0:1的胰岛素分泌信号基本相同的总体生物活性。
4.权利要求1到3任一项的表达盒,其中异源序列编码选自激素、细胞因子、受体激动剂、受体拮抗剂、信息素和酶的多肽。
5.权利要求4的表达盒,其中多肽是生长激素。
6.权利要求5的表达盒,其中多肽是促生长素。
7.权利要求1到6任一项的表达盒,还包括使异源序列脉冲表达的一种或多种调控序列。
8.包括权利要求1到7任一项的表达盒的载体。
9.包括权利要求1到7任一项的表达盒的重组细胞。
10.权利要求9的重组细胞,其中细胞是细菌、酵母、昆虫或哺乳动物细胞。
11.权利要求10的重组细胞,其中细胞是哺乳动物细胞。
12.权利要求11的重组细胞,其中细胞是大鼠成肌细胞(L6)。
13.制备多肽的方法,包括在可以表达和分泌该多肽的条件下培养权利要求9到12任一项的重组细胞,并可选地包括分离该多肽。
14.用于植入宿主的胶囊,胶囊包括包封权利要求9到12任一项的重组细胞的半渗透膜。
15.权利要求14的胶囊,其中半渗透膜是藻酸盐-聚-L-赖氨酸-藻酸盐(APA)膜。
16.向宿主给予多肽的方法,其中该方法包括向宿主给予权利要求1到7任一项的表达盒。
17.向宿主给予多肽的方法,其中该方法包括在宿主中植入权利要求14或15的胶囊。
18.权利要求16或17的方法,其中宿主是动物或人。
19.权利要求18的方法,其中宿主是家畜。
20.权利要求19的方法,其中家畜是猪。
21.向猪给予促生长素的方法,其中该方法包括在猪中植入包括包封重组细胞的半渗透膜的胶囊,所述重组细胞包括和表达一种表达盒,所述表达盒包括编码胰岛素分泌信号的序列,所述胰岛素分泌信号与编码促生长素的异源序列有效连接,其中所述膜对表达的促生长素是可通透的。
22.权利要求21的方法,其中胰岛素分泌信号具有SEQ ID NO:1所示的氨基酸序列。
23.权利要求21的方法,其中胰岛素分泌信号是修饰的胰岛素分泌信号,其具有与氨基酸序列为SEQ ID NO:1的胰岛素分泌信号基本相同的总体生物活性。
24.权利要求21到23任一项的方法,其中重组细胞是哺乳动物细胞。
25.权利要求24的方法,其中哺乳动物细胞是大鼠成肌细胞(L6)。
26.权利要求21到25任一项的方法,其中半渗透膜是藻酸盐-聚-L-赖氨酸-藻酸盐(APA)膜。
27.权利要求21到26任一项的方法,其中向猪植入一个或多个胶囊,这些胶囊足以分泌至少30ng/ml的促生长素。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP6556A AUPP655698A0 (en) | 1998-10-16 | 1998-10-16 | Delivery system for porcine somatotropin |
AUPP6556 | 1998-10-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1323348A true CN1323348A (zh) | 2001-11-21 |
CN1325650C CN1325650C (zh) | 2007-07-11 |
Family
ID=3810777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998122564A Expired - Fee Related CN1325650C (zh) | 1998-10-16 | 1999-10-18 | 猪促生长素传递系统 |
Country Status (14)
Country | Link |
---|---|
US (2) | US6967089B1 (zh) |
EP (1) | EP1121449A4 (zh) |
JP (1) | JP2002527112A (zh) |
KR (1) | KR20010099687A (zh) |
CN (1) | CN1325650C (zh) |
AU (1) | AUPP655698A0 (zh) |
BR (1) | BR9914547A (zh) |
CA (1) | CA2346799A1 (zh) |
ID (1) | ID30149A (zh) |
MX (1) | MXPA01003810A (zh) |
NZ (1) | NZ510943A (zh) |
RU (1) | RU2268940C2 (zh) |
WO (1) | WO2000023601A1 (zh) |
ZA (1) | ZA200102965B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109929849A (zh) * | 2019-03-18 | 2019-06-25 | 华南农业大学 | 一种优化的pGH基因、蛋白及在提高毕赤酵母分泌表达pGH产量和活性中的应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPP655698A0 (en) * | 1998-10-16 | 1998-11-05 | Commonwealth Scientific And Industrial Research Organisation | Delivery system for porcine somatotropin |
EP4154914A1 (en) * | 2015-05-07 | 2023-03-29 | University of South Florida | Modified ube3a gene for a gene therapy approach for angelman syndrome |
WO2019147623A2 (en) * | 2018-01-23 | 2019-08-01 | Virginia Commonwealth University | Mda-7/il secretory variants and methods of use |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR70279B (zh) * | 1979-09-12 | 1982-09-03 | Univ California | |
US4923808A (en) | 1985-03-12 | 1990-05-08 | Genentech, Inc. | Method for identifying mutants secreting high levels of heterologous proteins |
GB8529014D0 (en) * | 1985-11-25 | 1986-01-02 | Biogen Nv | Enhanced secretion of heterologous proteins |
US4992367A (en) * | 1986-05-12 | 1991-02-12 | Hoffmann-La Roche Inc. | Enhanced expression of human interleukin-2 in mammalian cells |
US5200509A (en) * | 1987-04-06 | 1993-04-06 | Celtrix Pharmaceuticals, Inc. | Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides |
US5681562A (en) | 1991-06-25 | 1997-10-28 | Sidney Kimmel Cancer Center | Lymphokine gene therapy of cancer |
US5932211A (en) | 1991-11-12 | 1999-08-03 | Women's And Children's Hospital | Glycosylation variants of iduronate 2-sulfatase |
US5545423A (en) | 1991-11-25 | 1996-08-13 | Vivorx, Inc. | Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials |
US5858751A (en) * | 1992-03-09 | 1999-01-12 | The Regents Of The University Of California | Compositions and methods for producing sialyltransferases |
US5641665A (en) | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US5856159A (en) | 1996-03-27 | 1999-01-05 | Cytel Corporation | Production of galactosyltransferase |
WO2000014216A1 (en) * | 1998-09-04 | 2000-03-16 | Zk Pharmaceuticals, Inc. | Method for selecting peptides inhibiting viral surface protein binding to cell surface receptor |
AUPP655698A0 (en) * | 1998-10-16 | 1998-11-05 | Commonwealth Scientific And Industrial Research Organisation | Delivery system for porcine somatotropin |
US20040053276A1 (en) * | 2000-09-22 | 2004-03-18 | Yasuaki Ito | Novel tissue-specific secretory polypeptide and dna thereof |
EP1360964A4 (en) * | 2001-01-19 | 2004-03-31 | Takeda Chemical Industries Ltd | USE OF A GALANINE-LIKE PEPTID |
US6811785B2 (en) * | 2001-05-07 | 2004-11-02 | Mount Sinai School Of Medicine Of New York University | Multivalent MHC class II—peptide chimeras |
-
1998
- 1998-10-16 AU AUPP6556A patent/AUPP655698A0/en not_active Abandoned
-
1999
- 1999-10-18 NZ NZ510943A patent/NZ510943A/en unknown
- 1999-10-18 ID IDW00200101076A patent/ID30149A/id unknown
- 1999-10-18 MX MXPA01003810A patent/MXPA01003810A/es unknown
- 1999-10-18 KR KR1020017004624A patent/KR20010099687A/ko not_active Application Discontinuation
- 1999-10-18 BR BR9914547-2A patent/BR9914547A/pt not_active Application Discontinuation
- 1999-10-18 EP EP99970688A patent/EP1121449A4/en not_active Withdrawn
- 1999-10-18 RU RU2001113279/13A patent/RU2268940C2/ru not_active IP Right Cessation
- 1999-10-18 CA CA002346799A patent/CA2346799A1/en not_active Abandoned
- 1999-10-18 CN CNB998122564A patent/CN1325650C/zh not_active Expired - Fee Related
- 1999-10-18 JP JP2000577308A patent/JP2002527112A/ja not_active Withdrawn
- 1999-10-18 WO PCT/AU1999/000896 patent/WO2000023601A1/en not_active Application Discontinuation
- 1999-10-18 US US09/807,519 patent/US6967089B1/en not_active Expired - Fee Related
-
2001
- 2001-04-10 ZA ZA200102965A patent/ZA200102965B/en unknown
-
2005
- 2005-06-27 US US11/166,340 patent/US20060062772A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109929849A (zh) * | 2019-03-18 | 2019-06-25 | 华南农业大学 | 一种优化的pGH基因、蛋白及在提高毕赤酵母分泌表达pGH产量和活性中的应用 |
CN109929849B (zh) * | 2019-03-18 | 2021-05-04 | 华南农业大学 | 一种优化的pGH基因、蛋白及在提高毕赤酵母分泌表达pGH产量和活性中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1325650C (zh) | 2007-07-11 |
AUPP655698A0 (en) | 1998-11-05 |
EP1121449A4 (en) | 2004-12-01 |
US20060062772A1 (en) | 2006-03-23 |
CA2346799A1 (en) | 2000-04-27 |
NZ510943A (en) | 2004-10-29 |
ID30149A (id) | 2001-11-08 |
WO2000023601A1 (en) | 2000-04-27 |
EP1121449A1 (en) | 2001-08-08 |
MXPA01003810A (es) | 2003-10-14 |
BR9914547A (pt) | 2001-06-26 |
JP2002527112A (ja) | 2002-08-27 |
KR20010099687A (ko) | 2001-11-09 |
RU2268940C2 (ru) | 2006-01-27 |
US6967089B1 (en) | 2005-11-22 |
ZA200102965B (en) | 2001-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chang et al. | Delivery of recombinant gene products with microencapsulated cells in vivo | |
CN101610793B (zh) | 长效药物制剂 | |
JP3244696B2 (ja) | ヒト筋肉細胞の単離、増殖および分化 | |
CN1043631A (zh) | 用于控制释放多肽的组合物 | |
EP0289034B1 (en) | Transkaryotic implantation | |
CN1020473C (zh) | 编码表现有人粒性巨噬细胞和嗜伊红细胞生长因子活性之多肽的cDNA克隆 | |
US6093393A (en) | Methods for preparing and using clonogenic fibroblasts and transfected clonogenic fibroblasts | |
CN103260649A (zh) | 长效药物制剂 | |
Hortelano et al. | Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules | |
CN1325650C (zh) | 猪促生长素传递系统 | |
JPH05505944A (ja) | 修飾肝細胞およびその用途 | |
CA2131709C (en) | Immune-enhancing agent for therapeutic use in immunocompromised hosts | |
CN1143371A (zh) | 司登尼亚蛋白小体-司登尼亚钙蛋白 | |
CN1744814A (zh) | 从非转基因哺乳动物乳腺生产重组蛋白质的方法 | |
CN1033759C (zh) | 猪生长激素类似物 | |
JP2002504365A (ja) | 乳房上皮細胞への遺伝子転移を伴うトランスソマチクス | |
CN1375500A (zh) | 新的干扰素-胸腺肽融合蛋白及其制法和用途 | |
JP2001526043A (ja) | 標的体細胞トランスジェネシスを誘導するためのtgc−法 | |
AU758126B2 (en) | Delivery system for porcine somatotropin | |
CN1094974C (zh) | 表达人白细胞介素12的重组腺病毒及其制法和用途 | |
RU2001113279A (ru) | Система доставки свиного соматотропина | |
WO2024108955A1 (zh) | 乙型肝炎疫苗 | |
CN1269963C (zh) | 心房肽基因转染细胞微囊 | |
CN100556455C (zh) | 一种用于预防和治疗i型糖尿病的药物复合物及其应用 | |
CN1381582A (zh) | 靶向性、高表达人粒细胞巨噬细胞集 落刺激因子的重组腺病毒及其制法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |